Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $16.3 million.

  • Artiva Biotherapeutics' Cash from Investing Activities rose 112.46% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.4 million, marking a year-over-year increase of 137.99%. This contributed to the annual value of -$120.5 million for FY2024, which is 363.77% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Cash from Investing Activities of $16.3 million as of Q3 2025, which was down 22.93% from $21.1 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Cash from Investing Activities registered a high of $21.1 million during Q2 2025, and its lowest value of -$130.6 million during Q3 2024.
  • Over the past 3 years, Artiva Biotherapeutics' median Cash from Investing Activities value was $1.3 million (recorded in 2024), while the average stood at -$8.5 million.
  • As far as peak fluctuations go, Artiva Biotherapeutics' Cash from Investing Activities slumped by 26,396.55% in 2024, and later skyrocketed by 1,465.75% in 2025.
  • Artiva Biotherapeutics' Cash from Investing Activities (Quarterly) stood at -$2.7 million in 2023, then spiked by 63.79% to -$966,000 in 2024, then soared by 112.46% to $16.3 million in 2025.
  • Its last three reported values are $16.3 million in Q3 2025, $21.1 million for Q2 2025, and $10.0 million during Q1 2025.